Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine
Само за регистроване кориснике
2019
Аутори
Mihajlović, Marija
Ninić, Ana

Sopić, Miron

Miljković, Milica

Stefanović, Aleksandra

Vekić, Jelena

Spasojević-Kalimanovska, Vesna

Zeljković, Dejan
Trifunović, Bratislav
Stjepanović, Željka
Zeljković, Aleksandra

Чланак у часопису (Објављена верзија)

Метаподаци
Приказ свих података о документуАпстракт
Background: Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC. Methods: Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin’s concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism. Results: Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (p < 0.001 and p < 0.05, respectively), while res...istin mRNA levels were lower (p < 0.001). Negative association existed among plasma resistin and HDL-C concentrations (ρ = − 0.280; p < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC = 0.898). We found no associations of rs1862513 with the examined markers. Conclusions: Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin’s secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.
Кључне речи:
Adenylate cyclase-associated protein 1 / Colorectal cancer / High-density lipoprotein cholesterol / Paraoxonase-1 activity / Predictive preventive personalized medicine / ResistinИзвор:
EPMA Journal, 2019, 10, 307-316Издавач:
- Springer
Финансирање / пројекти:
DOI: 10.1007/s13167-019-00178-x
ISSN: 1878-5077
WoS: 000489790500009
Scopus: 2-s2.0-85069475188
Институција/група
PharmacyTY - JOUR AU - Mihajlović, Marija AU - Ninić, Ana AU - Sopić, Miron AU - Miljković, Milica AU - Stefanović, Aleksandra AU - Vekić, Jelena AU - Spasojević-Kalimanovska, Vesna AU - Zeljković, Dejan AU - Trifunović, Bratislav AU - Stjepanović, Željka AU - Zeljković, Aleksandra PY - 2019 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3458 AB - Background: Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC. Methods: Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin’s concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism. Results: Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (p < 0.001 and p < 0.05, respectively), while resistin mRNA levels were lower (p < 0.001). Negative association existed among plasma resistin and HDL-C concentrations (ρ = − 0.280; p < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC = 0.898). We found no associations of rs1862513 with the examined markers. Conclusions: Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin’s secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development. PB - Springer T2 - EPMA Journal T1 - Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine VL - 10 SP - 307 EP - 316 DO - 10.1007/s13167-019-00178-x ER -
@article{ author = "Mihajlović, Marija and Ninić, Ana and Sopić, Miron and Miljković, Milica and Stefanović, Aleksandra and Vekić, Jelena and Spasojević-Kalimanovska, Vesna and Zeljković, Dejan and Trifunović, Bratislav and Stjepanović, Željka and Zeljković, Aleksandra", year = "2019", abstract = "Background: Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC. Methods: Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin’s concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism. Results: Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (p < 0.001 and p < 0.05, respectively), while resistin mRNA levels were lower (p < 0.001). Negative association existed among plasma resistin and HDL-C concentrations (ρ = − 0.280; p < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC = 0.898). We found no associations of rs1862513 with the examined markers. Conclusions: Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin’s secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.", publisher = "Springer", journal = "EPMA Journal", title = "Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine", volume = "10", pages = "307-316", doi = "10.1007/s13167-019-00178-x" }
Mihajlović, M., Ninić, A., Sopić, M., Miljković, M., Stefanović, A., Vekić, J., Spasojević-Kalimanovska, V., Zeljković, D., Trifunović, B., Stjepanović, Ž.,& Zeljković, A.. (2019). Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine. in EPMA Journal Springer., 10, 307-316. https://doi.org/10.1007/s13167-019-00178-x
Mihajlović M, Ninić A, Sopić M, Miljković M, Stefanović A, Vekić J, Spasojević-Kalimanovska V, Zeljković D, Trifunović B, Stjepanović Ž, Zeljković A. Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine. in EPMA Journal. 2019;10:307-316. doi:10.1007/s13167-019-00178-x .
Mihajlović, Marija, Ninić, Ana, Sopić, Miron, Miljković, Milica, Stefanović, Aleksandra, Vekić, Jelena, Spasojević-Kalimanovska, Vesna, Zeljković, Dejan, Trifunović, Bratislav, Stjepanović, Željka, Zeljković, Aleksandra, "Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine" in EPMA Journal, 10 (2019):307-316, https://doi.org/10.1007/s13167-019-00178-x . .